NCT07820254Recruiting
Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients
A Clinical Study on Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
The goal of this observational study is to learn about the inspiratory flow rate capability in patients with pulmonary fibrosis (IPF or PPF) when using inhaler devices with different resistances. The main questions it aims to answer are: What is the peak inspiratory flow rate (PIFR) that patients with pulmonary fibrosis can achieve through a medium-resistance inhaler device? What is the peak inspiratory flow rate (PIFR) that patients with pulmonary fibrosis can achieve through a high-resistance inhaler device? What is the inspiratory time (EIT) for each resistance level? Participants will use a portable device called In-Check™ DIAL G16, which simulates the resistance of different dry powder inhalers. Each participant will perform two breathing tests at a medium-resistance setting and two breathing tests at a high-resistance setting, with a 2-minute rest between settings. The device measures how fast air is breathed in and how long each breath lasts. This study will enroll 60 patients diagnosed with IPF or PPF at Shanghai Pulmonary Hospital. Participants will be involved for approximately 30 to 60 minutes, including training on how to use the device and the breathing tests. The study involves no drugs or invasive procedures.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 10 Sept 2026
- Start date
- 10 Jan 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Diseases
- Idiopathic pulmonary fibrosis
- NCT number
- NCT07820254
What you commit to
- Study type: Observational
- Planned participants: 60
- From 10 Jan 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with impaired consciousness, dementia, or various psychiatric disorders.
- Patients with major diseases or conditions other than the IPF under study that, in the investigator's judgment, may put the patient at risk by participating in the trial.
Other
- Patients unable to operate the inspiratory flow measurement device as instructed by the investigator.
- Any participant deemed unsuitable for enrollment by the investigator.
Who the study is looking for
- Age 18-80 years (inclusive), either sex.
- Diagnosis of pulmonary fibrosis (IPF or PPF) according to the ATS/ERS/JRS/ALAT 2022 guidelines (with traceable diagnostic evidence such as medical records, confirmed by a radiologist).
- Forced vital capacity (FVC) ≥ 45% of predicted normal value within 2 months before screening.
- Diffusing capacity for carbon monoxide (DLCO) \> 25% of predicted normal value within 2 months before screening.
- Voluntary participation with written informed consent.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Pulmonary Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.